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Abstract
 
A mutation in the gene encoding for the liver mitochondrial aldehyde dehydrogenase
(
 
ALDH2–2
 
), present in some Asian populations, lowers or abolishes the activity of this enzyme
and results in elevations in blood acetaldehyde upon ethanol consumption, a phenotype that
greatly protects against alcohol abuse and alcoholism. We have determined whether the admin-
istration of antisense phosphorothioate oligonucleotides (ASOs) can mimic the low-activity
ALDH2–2 Asian phenotype. Rat hepatoma cells incubated for 24 h with an antisense oligonu-
cleotide (ASO-9) showed reductions in ALDH2 mRNA levels of 85% and ALDH2 (half-life
of 22 h) activity of 55% equivalent to a 
 
 
 
90% inhibition in ALDH2 synthesis. Glutamate de-
hydrogenase mRNA and activity remained unchanged. Base mismatches in the oligonucle-
otide rendered ASO-9 virtually inactive, confirming an antisense effect. Administration of
ASO-9 (20 mg/kg/day for 4 d) to rats resulted in a 50% reduction in liver ALDH2 mRNA, a
40% inhibition in ALDH2 activity, and a fourfold (
 
P 
 
  
 
0.001) increase in circulating plasma
acetaldehyde levels after ethanol (1 g/kg) administration. Administration of ASO-9 to rats by
osmotic pumps led to an aversion (
 
 
 
61%, 
 
P 
 
  
 
0.02) to ethanol. These studies provide a proof
of principle that specific inhibition of gene expression can be used to mimic the protective ef-
fects afforded by the ALDH2–2 phenotype.
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Introduction
 
Research on the genetics of alcoholism indicates that there
are (a) predisposing and (b) protective factors in the devel-
opment of alcoholism. The heritability of predisposing fac-
tors has been estimated to be 40–60% (1), while the pro-
tective genetic influence can approach 100% (2). The
protective genetic influence is associated with a low activity
of liver mitochondrial aldehyde dehydrogenase (ALDH2),
 
*
 
an enzyme that plays a major role in the detoxification of
acetaldehyde generated in the metabolism of ethanol. In
some Asian populations, a dominant mutation in the gene
that codes for this enzyme (
 
ALDH2–2
 
) renders the enzyme
largely inactive (3, 4). Individuals carrying the 
 
ALDH2–2
 
allele who consume small amounts of alcohol display ele-
vated blood acetaldehyde levels and dysphoric effects that
include dizziness, nausea, hypotension, and palpitations (5).
It has been postulated that many of the intoxicating effects
of ethanol are accentuated in subjects carrying the
 
ALDH2–2
 
 allele (6, 7). Overall, the protective effect of the
 
ALDH2–2
 
 allele against alcohol abuse and alcoholism
ranges from 66 and 90% for heterozygotes to 100% for ho-
mozygotes (2, 8–12).
Disulfiram (Anatabuse
 
®
 
), a nonspecific drug that inhibits
the activity of ALDH2 by reacting with sulfhydryl groups
in the enzyme (13), has been shown to be effective in the
treatment of alcoholism (14). However, a major problem
with disulfiram is the lack of patient compliance which is
mainly due to its side effects including sensory and motor
neuropathies, optic neuritis, orthostatic hypotension, and
hypersensitivity reactions (15–19). Hence, a new approach
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Antisense-induced Aversion to Alcohol
 
to specifically inhibit ALDH2 without the undesirable side
effects of disulfiram would be a welcomed development in
the treatment of alcoholism.
With the advent of gene pharmacology, new ap-
proaches now exist by which the expression of a single
gene can be inhibited. Antisense phosphorothioate oligo-
nucleotides (ASOs) with a sequence complementary to the
primary RNA transcripts or to mRNA can inhibit gene
expression in a specific manner (20). The clinical applica-
tions of antisense are becoming accepted. An ASO (Vit-
ravene™) designed to inhibit human cytomegalovirus rep-
lication was approved for commercialization by the FDA.
In addition, over 20 other ASOs are undergoing clinical
trials (www.recap.com).
In 1997, a consensus conference on the design of anti-
sense concluded that a large number of ASOs (
 
 
 
30) had to
be designed and tested empirically to find one effective an-
tisense molecule (21). However, recent work in our labo-
ratory led to the finding that about one half of the most
active antisense deoxyoligonucleotides reported in the lit-
erature contain a 5
 
 
 
-TCCC-3
 
 
 
 motif in the molecule (22).
Antisense deoxyoligonucleotides containing the TCCC
motif and designed prospectively were shown to act by
greatly reducing mRNA levels (22). This is in line with re-
cent postulates that the RNA moiety of DNA-RNA hy-
brids is hydrolyzed by RNase H (23).
Here, we report studies on a phosphorothioate-modified
deoxyoligonucleotide containing the 5
 
 
 
-TCCC-3
 
 
 
 motif
directed against ALDH2 mRNA, which was shown to be
most effective in: (a) reducing ALDH2 mRNA levels and
mitochondrial ALDH2 activity in rat hepatoma cells in
vitro, (b) reducing liver ALDH2 mRNA and mitochon-
drial ALDH2 activity in rats in vivo, (c) increasing fourfold
the plasma acetaldehyde levels after an oral dose of ethanol,
and (d) eliciting a marked reduction in ethanol consump-
tion. Overall, we present studies in which an antisense
molecule designed to anneal to ALDH2 mRNA in the rat
results in a phenotype that mimics the elevated plasma ace-
taldehyde levels observed in Asians who have a low
ALDH2 activity (ALDH2–2) and consume ethanol. Such
an antisense molecule led to a marked reduction in volun-
tary ethanol consumption in animals.
 
Materials and Methods
 
Chemicals
 
All chemicals used were purchased from Sigma-Aldrich, ex-
cept for sucrose, sodium pyrophosphate, sodium phosphate, mag-
nesium chloride, perchloric acid, hydrochloric acid, acetonitrile,
and isooctane, which were purchased from Fisher Scientific.
 
ASOs
 
Phosphorothioate oligonucleotides with specific base se-
quences used for in vitro studies were manufactured by Genset
Corp. Purified ASO-9 for in vivo work and for the last two in
vitro studies was purchased from Hybridon. For the in vivo
study, HPLC-purified ASO-9 was dissolved in PBS at a concen-
tration of 20 mg/ml. A large stock solution was prepared a day
ahead of the initiation of the in vivo study and aliquoted into sep-
arate tubes to prevent any freeze-thaw cycles, which were stored
at 
 
 
 
70
 
 
 
C until it was needed for dosing.
 
Cell Culture
 
Rat hepatoma cell line H4-II-E-C3 (H4) (American Type
Culture Collection CRL-1600) was purchased from American
Type Culture Collection. Cells were grown in Dulbecco’s modi-
fied Eagle’s medium containing 4.5 g/liter of 
 
l
 
-glutamine (Cell-
gro
 
®
 
; Mediatech), 20% horse serum, and 5% fetal bovine serum
(Life Technologies) in 10% CO
 
2
 
 at 37
 
 
 
C. All delivery of oligonu-
cleotides and incubations were conducted in the presence of 10%
CO
 
2
 
 at 37
 
 
 
C.
 
In Vitro Oligonucleotide Delivery
 
H4 cells were seeded 18–24 h before the delivery of phosphor-
othioate oligonucleotides at a density of 2.5 
 
 
 
 10
 
6
 
 cells/100-mm
culture dish. Oligonucleotides were prepared using cationic lipo-
somes, Lipofectamine Plus™ (Life Technologies). For each 100-
mm culture dish to be treated, varying amounts of oligo in 2.5 to
10 
 
 
 
l (800 
 
 
 
M stock) were added to 360 
 
 
 
l serum-free Dul-
becco’s modified Eagle’s medium containing 4.5 g/liter of 
 
l
 
-glu-
tamine (DMEM) which were mixed with 27 
 
 
 
l PLUS reagent
 
®
 
in a microcentrifuge tube, while in another microcentrifuge tube,
40 
 
 
 
l of Lipofectamine (2 mg/ml) was added to 360 
 
 
 
l DMEM.
The microcentrifuge tubes were incubated at room temperature
for 15 min and then the contents of the microcentrifuge tube
containing the oligo and PLUS reagent was added dropwise to
the microcentrifuge tube containing lipofectamine and DMEM.
The combined mixture was then incubated for an additional 15
min at room temperature to form the Lipofectamine Plus-oligo
complex. The final Lipofectamine Plus-oligo complex (800 
 
 
 
l)
was added to 7.2 ml of serum-free DMEM at 37
 
 
 
C. The 8.0-ml
mixture constituted the complete culture medium in a 100-mm
culture dish (final concentrations of ASO-9 ranged from 0.25 to
1.0 
 
 
 
M). Prior to the addition of the Lipofectamine Plus-oligo
complex, the medium with serum was removed from the cells
and the final 8 ml of prepared Lipofectamine Plus-oligo complex
was added to the culture dish and incubated for 6 h in the absence
of serum. 30 min before the end of the 6-h delivery, serum was
added back to the cells for overnight culture. As the oligo con-
centration was reduced by addition of serum, a second addition of
Lipofectamine Plus-oligo complex (280 
 
 
 
l) was prepared to
maintain the desired concentration. A second addition was pre-
pared using oligo, 9.45 
 
 
 
l PLUS reagent, and 14 
 
 
 
l lipo-
fectamine. The final Lipofectamine Plus-oligo complex was
added to the culture dish at 6 h with a mixture of 20% horse (2.2
ml) and 5% fetal bovine serum (0.6 ml) and incubated for an ad-
ditional 18 h.
 
Mitochondria Isolation
 
Upon completion of incubations, H4 cells were collected by
removing the culture medium containing the Lipofectamine
Plus-oligo complex and washing once with 5 ml ice-cold mito-
chondrial isolation buffer comprised of 0.25 mM sucrose in 10
mM Tris-HCl, pH 7.4. Cells were collected and transferred to an
ice-cold conical tube for centrifugation at 152 
 
g
 
 for 5 min at 4
 
 
 
C
to pellet the cells which were then resuspended in 200 
 
 
 
l of the
isolation buffer. The concentrated cellular suspension was ho-
mogenized and fractionated as described previously (24). The fi-
nal purified mitochondrial pellet was resuspended in 250 
 
 
 
l of 50
mM sodium pyrophosphate, pH 9.0, immediately frozen in liq-
uid nitrogen, and stored at 
 
 
 
70
 
 
 
C until the time of analysis. 
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Prior to analysis, the mitochondria were thawed on ice, solubi-
lized by adding 1% Triton X-100, and incubated for 15 min on
ice. In some studies (see study III, Table I and Table III), the Tri-
ton X–treated mitochondria were transferred to an ultracentri-
fuge tube and centrifuged at 4
 
 
 
C for 30 min at 69,500 
 
g
 
 to re-
move insoluble particulates.
Mitochondria from rat livers collected from control (PBS) and
ASO-9–treated animals were isolated in a similar fashion as de-
scribed previously (24). Soluble mitochondrial protein content
isolated from H4 cells or liver was determined by the Micro BCA
Protein Assay Reagent Kit (Pierce Chemical Co.) as described by
the manufacturer with bovine serum albumin as the standard.
 
Determination of ALDH and Glutamate Dehydrogenase Activity
 
The low-Km ALDH activity in the isolated mitochondria was
assayed as described previously (25) with minor modifications.
The assay was initiated by the addition of propionaldehyde to a
final concentration of 14 
 
 
 
M, 80 
 
 
 
M NAD, and 2.5 mM MgCl
 
2
 
(26). The reaction was linear with time, and ALDH activity was
expressed as nmoles NADH/min/mg protein. Glutamate dehy-
drogenase (GDH) was assayed as described with minor modifica-
tions (27). The assay was performed at 37
 
 
 
C in a 400-
 
 
 
l reaction
mixture containing 25 
 
 
 
g of soluble mitochondrial protein. The
reaction was linear with time, and GDH activity was expressed
as the oxidation of NADH to NAD
 
 
 
 in 
 
 
 
moles NAD/min/mg
protein.
 
Determination of ALDH2 Half-Life by Cycloheximide
 
Initial studies were conducted to determine the optimal con-
centration of cycloheximide (CHX) required to maximally in-
hibit protein synthesis in the H4 cells. Cells were seeded at a
density of 16 
 
 
 
 10
 
6
 
 cells/T75 flask 24 h before the treatment
with CHX to ensure that they were in a stationary phase. The
incubation medium containing serum was removed from the
cells and the cells were washed twice with 5 ml of methionine-
free DMEM (
 
l
 
-glutamine was added; Life Technologies). Cells
were then cultured for 1 h in 8 ml of methionine-free DMEM
containing 1, 3, 5, 7, or 10 
 
 
 
g/ml CHX, after which a 15-min
pulse of [
 
35
 
S]methionine (1.5 
 
 
 
Ci, SA 
 
  
 
1 CI/
 
 
 
M) was added
to the flask. After the pulse, [
 
35
 
S]methionine was removed from
the flask and the cells were washed twice with 5 ml PBS. Cells
were then lysed in 10 ml of 0.15 M KCl containing 1 mM
EDTA (pH 8.0) and processed for radioactivity determination es-
sentially as described earlier (28). The total cellular protein con-
tent of cells treated with or without CHX was determined as de-
scribed above.
The half-life of ALDH2 (time to reduce the activity by 50%)
in the H4 cells was determined in the presence of 5 
 
 
 
g/ml CHX.
H4 cells (3 replicates/time per point) were treated for 1, 5, 7, 12,
or 24 h with CHX in DMEM without serum present. The mito-
chondrial ALDH2 activity remaining at the different times of in-
cubation with CHX was then determined.
 
Sequencing of H4-II-E-C3 ALDH2–1 cDNA by Reverse 
Transcriptase PCR
 
The published cDNA sequence of the mitochondrial ALDH2
in the Sprague-Dawley rat (29) was used to design PCR primers
to amplify the cDNA obtained from the mRNA isolated from
the H4 cell line. Total cellular RNA was isolated using Tri-Rea-
gent
 
®
 
 (Molecular Research Center, Inc.) and the first strand
cDNA was made using a First Strand cDNA Synthesis Kit using
random hexamer primers (Amersham Pharmacia Biotech) ac-
cording to the manufacturer’s protocols. Three sets of PCR
primers were designed to amplify three fragments of 476, 753,
and 598 bp which combined constituted 96% of the published
Sprague-Dawley rat sequence. The PCR primers were as follows:
(476 bp, forward 5
 
 
 
-CACgCCTgAgCCgCCTg-3
 
 
 
, reverse
5
 
 
 
-gCTgAAgAAgTCgCCATCg-3
 
 
 
), (753 bp, forward 5
 
 
 
-
CgATggCgACTTCTTCAgC-3
 
 
 
, reverse 5
 
 
 
-CTTggCgATggT-
CATgCCA-3
 
 
 
), (598 bp, forward 5
 
 
 
-TggCATgACCATCgC-
CAAg-3
 
 
 
: reverse 5
 
 
 
-gAACCAgCATCCAgCACAg-3
 
 
 
). The
primers were synthesized by the Nucleic Acid Facility at Thomas
Jefferson University. All fragments were gel purified from 1%
agarose gels using QIAGEN’s gel purification kit (QIAGEN) and
the forward primers of each fragment were used in the sequenc-
ing reactions performed by Thomas Jefferson University-Nucleic
Acid Facility.
 
Determination of mRNA Expression by Competitive Reverse 
Transcriptase PCR
 
Competitive reverse transcriptase (RT)-PCR for ALDH2
mRNA was developed by first designing PCR primers to amplify
a 584-bp fragment from the Sprague-Dawley rat cDNA, donated
by Dr. Henry Weiner of Purdue University (West Lafayette, IN).
The primers (specific to mitochondrial ALDH) used to generate
the 584-bp fragment (referred to as a parent fragment) were as
follows: forward (F) 5
 
 
 
-ACgTggTggTgATgAAAgTg-3
 
 
 
 and
reverse (R1) 5
 
 
 
-gATgAAgTAACCACggTCTg-3
 
 
 
. The parent
fragment was amplified from the cDNA template under the fol-
lowing conditions: denaturation at 95
 
 
 
C for 3 min followed by
30 cycles at 95
 
 
 
C for 1 min, 63
 
 
 
C for 30 s, 72
 
 
 
C for 1.2 min, and
a final extension at 72
 
 
 
C for 10 min, and the resulting band was
purified from a 1% agarose gel. An internal standard, which
served as a competitor for primers of the parent fragment during
reverse transcription (as recombinant RNA, rcRNA) and PCR
(as first strand cDNA) reactions, was constructed using a similar
technique to that described previously (30). The same forward
primer mentioned above and a new reverse primer (NRP), com-
prised of the previous reverse primer sequence (R1, 5
 
 
 
-gAT-
gAAgTAACCACggTCTg) and an added reverse primer se-
quence (R2, 5
 
 
 
-ACACTgCgTTCCACgAATTC-3
 
 
 
), was used
to amplify a smaller internal standard fragment of 429 bp. The
40-mer NRP sequence (5
 
 
 
-gATgAAgTAACCACggTCTgA-
CACTgCgTTCCACgAATTC-3
 
 
 
) allowed the parent fragment
primers (F and R1) to also amplify the shorter artificial 429 bp in-
ternal standard that was spiked into experimental RNA samples at
varying amounts for competition with the mRNA of the parent
fragment.
The pGEM
 
®
 
-T Easy Vector (Promega) containing the 429-bp
recombinant DNA fragment (rcDNA) was transformed into
DH5
 
 
 
 competent 
 
Escherichia coli 
 
cells according to the manufac-
turer’s protocol (Life Technologies). The plasmid DNA was lin-
earized using NotI restriction enzyme and then purified before
use as template in the in vitro transcription reaction. The in vitro
transcription reaction for generating RNA to be used as competi-
tor in the RT-PCR reaction was performed using the Ribo-
Probe
 
®
 
 In Vitro Transcription System (Promega). The in vitro
transcription and RNA purification was performed as recom-
mended in the Promega technical manual.
A streamlined procedure similar to that reported by Vanden
Heuvel et al. (31) for design of a recombinant RNA (rcRNA)
was used to make the GDH internal standard which eliminated
any subcloning and relied only on PCR to obtain the rcDNA
template for in vitro transcription. The cDNA template obtained
for GDH was obtained by reverse transcription using random
hexamers (pd(N)6 20 ng/20 
 
 l RT reaction; Amersham Pharma-574 Antisense-induced Aversion to Alcohol
cia Biotech) and Omniscript RT (QIAGEN) from RNA isolated
from H4 cells. Primers were designed to amplify a 782-bp frag-
ment with a forward (F1) 5 -TCCTgggAggTCATCgAAg-3 
and a reverse (R) primer 5 -AACTgCTTCTCgCTggCTg-3 )
by PCR using similar conditions to those described above for
ALDH using 55 C for primer annealing. The PCR product was
run on a 1% agarose gel and the 782-bp parent fragment was pu-
rified from the gel. The purified fragment was then amplified
with a newly designed forward primer (NFP) and the same re-
verse primer (R) as mentioned above. The new forward primer
was constructed using a T7 promoter sequence (5 -TgTAATAC-
gACTCACTATAgggCgAAT) plus the previous forward primer
sequence (F1) (5 -TCCTgggAggTCATCgAAg-3 ), and a new
forward primer sequence (F2) (5 -CgTgAgTgTggATgAggTg-3 )
comprising a 65-mer: 5 -TgTAATACgACTCACTATAgggC-
gAATTCCTgggAggTCATCgAAgCgTgAgTgTggATgAggTg-
3 , which amplified a shorter fragment (718 bp), which was sub-
sequently used to prepare the GDH-mRNA internal standard.
For this purpose, the smaller artificial fragment (718 bp) contain-
ing the T7 promoter sequence was then used as the DNA tem-
plate for in vitro transcription to make RNA which served as the
GDH internal standard for competitive RT-PCR reactions with
sample RNA.
Sample analysis for ALDH or GDH mRNA expression was
performed using 2  g of total RNA spiked with a range of inter-
nal standard RNA (ALDH 0–100 pg and GDH 0–32 ng) de-
pending on the anticipated gene expression. Omniscript RT was
used for all the reverse transcription reactions according to the
QIAGEN protocol using random hexamers (Amersham Pharma-
cia Biotech) to prime first strand cDNA synthesis. The parent
fragment and internal standard bands were analyzed on a Kodak
Digital Science Image Station 440CF (Eastman Kodak Co.) by
analyzing the net intensity of the UV/fluorescence emitted by the
ethidium bromide in the bands. The actual amount of internal
standard that was needed to compete for amplification with the
parent fragment was determined by plotting the amount of inter-
nal standard against its corresponding net intensity ratio (internal
standard band/parent fragment band). Using a linear relationship,
the exact amount of internal standard needed to equally compete
with the amount of sample mRNA present was determined from
the linear regression equation when y   1.
Animals and Treatment
Intravenous Administration of ASO-9. Male Lewis rats (Harlan)
weighing 200–300 g were used. Prior to femoral vein catheteriza-
tion, all rats were acclimated for at least 3 d to their cages. All an-
imals were maintained on a 12 h light/dark cycle and had free ac-
cess to laboratory rodent diet 5001 (PMI Feeds, Inc.) and tap
water. Once animals were acclimated, surgery was performed to
insert a femoral venous catheter comprised of a flexible Tygon
plastic tubing (0.015 internal diameter [I.D.]   0.03 outer diame-
ter [O.D.]). Patency of catheters was maintained by using a lock
solution containing heparin (444 U/ml), dextrose (22%), and
streptokinase (16,667 U/ml), and a small piece of monofilament
which was inserted at the exposed end of the cannula to retain
the lock solution. Animals were treated for 4 d at 15 mg ASO-
9/kg/day via intravenous catheters. An oral ethanol challenge (1
g/kg) was administered on day 5 and animals were killed 1 h later
for determination of plasma acetaldehyde, ALDH, and GDH ac-
tivity and mRNA expression.
Intraperitoneal Administration of ASO-9. Male Lewis rats as de-
scribed above were surgically implanted with 2-ml osmotic
pumps (Alzet Minipump 2 M1–1®) containing a solution of 25
mg/ml ASO-9 in PBS or PBS (controls) in the interperitoneal
cavity. A priming dose of 20 mg/kg was administered intraperito-
neally after implantation of the pumps. The pumps delivered
ASO-9 at 24 mg/kg/day. 3 d after pump implantation, animals
were deprived of water overnight while rat chow remained ac-
cessible. After the overnight fluid deprivation, on day 4 animals
were offered 6% vol/vol ethanol as the only fluid and consump-
tion was measured at hourly intervals for 5 h. Rehydration is a
prime physiological drive and animals will initially consume the
fluid offered. After the initial bout, rejection to continue con-
suming the fluid freely available indicates an aversion to the fluid
offered. The general protocol follows that recently described (25).
Animals were videotaped to capture their behavior after ethanol
presentation (see Garver et al. in http://arc.tju.edu/egarver).
Acetaldehyde Determination by HPLC. Plasma acetaldehyde was
determined as described previously (25).
Statistics
Statistical analysis was performed for the datasets in Microsoft
Excel 1997. Significant inhibitions of treated versus control
groups were calculated using a two-sample t test assuming un-
equal variances. Statistical significance was demonstrated at a 95%
confidence level with P values   0.05. Where applicable, mean
values for groups were calculated, as well as the SEM.
Results
Low-Km Mitochondrial ALDH2 in Rat Hepatoma Cells and 
the Liver of the Lewis Rat
Lindahl and associates (32) have reported the existence
of a mitochondrial ALDH2–1 in rat hepatoma H4-II-
E-C3 cells (referred to as H4 cell line), with similar char-
acteristics to ALDH2 in rat and human liver mitochondria.
The ALDH2–1 cDNA sequence was reported for the
Sprague-Dawley rat by Farres et al. (29). As the H4 cell
line was derived from a tumor from an AxC-Buffalo rat
cross, it was necessary to confirm that the ALDH2–1
cDNA sequence in the H4 cell line and in the inbred
Lewis rat were similar to that reported for the Sprague-
Dawley rat. We confirmed by RT-PCR and subsequent
sequencing that the cDNA sequences of this isozyme in
H4 cells and in the Lewis rat are  99% homologous to the
cDNA sequence for which PCR primers were designed,
which comprised 96% of ALDH cDNA. We further con-
firmed the studies by Huang and Lindahl (32) showing
that ALDH2 activity is present in mitochondria of H4 cells
and has a Km for acetaldehyde below 1  M. Thus, the
mitochondrial ALDH activity measured in the H4 cells has
a similar high affinity for acetaldehyde as that in rat and
human liver mitochondria (33).
Reduction in ALDH2–1 Activity of H4 Cells Incubated in the 
Presence of ASO-9
Half-Life. When using an antisense molecule to inhibit
specific protein synthesis, the half-life of the preformed
protein must be considered. To determine the half-life of
the mature mitochondrial ALDH2 we used CHX to arrest
the synthesis of all cellular proteins, which allowed us to
measure the decay of the existing ALDH2 enzyme. We575 Garver et al.
first determined the minimal concentration of CHX re-
quired for maximal inhibition of protein synthesis in the
H4 cell, measured by the rate of incorporation of [35S]me-
thionine into total proteins. CHX at a concentration of 5
 g/ml produced the maximal inhibition of 35S incorpora-
tion. At this concentration of CHX methionine-derived
35S incorporation was inhibited by 85% over 24 h. The re-
sidual incorporation could be due to posttranslational in-
corporation of [35S]sulfate, and it was not further reduced
by increasing the concentrations of CHX. Cell viability
under these conditions exceeded 90%. Under these condi-
tions, ALDH2 activity in the H4 cells was reduced by 56%
from control values in 24 h. The calculated half-life of the
mature ALDH2 in the mitochondria was 22 h. Such a half-
life is in line with a half-life of 22 h also reported for Hela
cells transduced with human ALDH2–1 (34).
Effect of ASO-9. We present here the results of anti-
sense phosphorothioate deoxyoligonucleotide no. 9 (ASO-
9), the most effective of nine antisense molecules contain-
ing the TCCC motif studied. Data in Table I show that
after a 24-h incubation of H4 cells with ASO-9, mitochon-
drial ALDH2 activity was reduced by 54.9   10.7%
(mean   SEM). Lipofectamine alone or lipofectamine plus
control oligonucleotide(s) showed no reductions in ALDH2
activity. Given a half-life of 22 h, it was determined that
the de novo synthesis of ALDH2–1 was inhibited by  95%
after the 24 h of exposure to ASO-9 (Table I). Although
ASO-9 proved to be very effective in inhibiting the
synthesis of ALDH2, the exact mechanism by which this
molecule elicited its effects was unknown. Thus, studies
were conducted to determine whether ASO-9 reduced
ALDH2–1 mRNA levels.
Reduction in ALDH2 mRNA Levels Induced by ASO-9 on 
H4 Cells
The steady-state level of ALDH2 mRNA was deter-
mined by quantitative competitive RT-PCR as described
in Materials and Methods. Table II shows that after a 24-h
treatment with ASO-9, ALDH2 mRNA in the H4 cells
was reduced by 84.8   4.7%. This result suggests that the
mechanism of action for ASO-9 is likely mediated by
RNA hydrolysis by RNase H.
Specificity
Sequence. The effect of minor sequence changes on the
ASO-9 molecule was tested by incubating cells with phos-
phorothioate oligonucleotides containing 2-, 3-, or 4-base
mismatches compared with ASO-9. One of the mis-
matches was always located in the “TCCC” motif. The
studies showed that mismatches of 2-, 3-, or 4 bases in
ASO-9 blunted the oligonucleotide’s ability to reduce the
levels of mRNA. The greater the number of mismatches
incorporated into the sequence of ASO-9, the less effec-
tive the modified ASO-9 became (Table II; experiments 4
and 6).
mRNA Levels. The specificity of ASO-9 was also dem-
onstrated by determining mRNA levels of ALDH2 and of
GDH, another mitochondrial enzyme, in the same cells.
Fig. 1 shows the reduction in mRNA ALDH2 afforded by
ASO-9 (see Fig. 1, A1) and its ineffectiveness on GDH
mRNA levels (Fig. 1, B1).
In Vivo Inhibition of ALDH2 Activity and mRNA by 
Antisense Oligonucleotide ASO-9
As ASO-9 proved to be most effective in reducing
ALDH2 activity in cell culture and was both sequence and
gene specific for ALDH2, we determined whether this
molecule could also reduce the activity of hepatic ALDH2
in vivo. The activity of GDH was determined as a control
mitochondrial enzyme. ALDH2 and GDH gene expression
(mRNA) were also determined in vivo. Antisense ASO-9
was administered for 4 d via an indwelling femoral vein
catheter with either ASO-9 (15 mg/kg) or PBS. 24 h after
the last dose of ASO-9 or PBS, animals received an oral
dose of 1 g/kg ethanol (from a solution of 7% wt/vol in
water) and were killed 60 min later for the determination
of mRNA levels, enzymatic activities, and plasma acetalde-
hyde levels. Treatment with ASO-9 led to a 50% reduction
Table I. Effect of ASO-9 on the Activity of the Low Km ALDH2 in Mitochondria of H4-II-E-C3 Rat Hepatoma Cells
 ALDH2 activity (nmoles/min/mg protein)
Control
(no lipofectamine)
Lipofectamine
(no oligo)
Lipofectamine
plus control oligoa
Lipofectamine
plus ASO-9b
Inhibitionc
(%) P value
Study Id 18.4   0.8 (4) 16.4   3.1 (4) 15.9   3.4 (4) 3.9   1.4 (4) 76.2  0.02
Study IId 14.0   2.2 (4) 7.5   1.3 (4) 46.5  0.02
Study IIIe 37.1   3.4 (4) 21.5   4.0 (4) 42.1  0.02
Where applicable, all oligonucleotides were kept at 1  M throughout the 24-h incubation.
aSequence 5 -CAgATgACCTCCCCCgTggAA-3 .
bSequence 5 -TCCTCCTTgTTCCCTTCggCT-3 .
cInhibition of ASO-9 with respect to lipofectamine alone. The calculated inhibition of ASO-9 based on the half-life of 22 h of ALDH2-1 was
98.1   19%. Values reported as mean   SEM were applicable.
dStudies I and II were conducted with mitochondrial fractions resuspended in 1% Triton X-100.
eStudy III was conducted with mitochondrial fractions resuspended in 1% Triton X-100 and centrifuged to remove nonsoluble debris.576 Antisense-induced Aversion to Alcohol
in ALDH2 mRNA compared with PBS control animals
(Table III). Administration of ASO-9 reduced ALDH2 ac-
tivity by 38–45% and led to a fourfold increase in plasma
acetaldehyde levels after ethanol administration, compared
with acetaldehyde levels in control animals that received
the same dose of ethanol (Table IV). GDH activity and
GDH mRNA levels were not affected by ASO-9, thus also
demonstrating in vivo the specificity of ASO-9 on ALDH2
gene expression (Tables III and IV).
Inhibition of Ethanol Consumption after Treatment with ASO-9
Studies were performed to determine if ASO-9 could es-
tablish an aversion to ethanol and reduce ethanol consump-
tion. The animal model used was essentially as reported
previously (25) to test a drug-induced aversion to ethanol.
Rats were surgically implanted with osmotic pumps which
delivered ASO-9 at 24 mg/kg/day intraperitoneally. 3 d af-
ter pump implantation, animals were deprived of water
overnight. Thereafter, animals were offered 6% vol/vol
ethanol as the only fluid, and consumption was measured at
hourly intervals for 5 h. A reduction in ethanol consump-
tion after the first bout indicates an aversion to the fluid of-
fered. Cumulative ethanol consumption (mean   SEM) at
each hourly interval is shown in Fig. 2. Initial ethanol con-
sumption was similar in both the ASO-9 and control (PBS)
groups during the first hour of ethanol presentation,
amounting to 1.12   0.09 g ethanol/kg (ASO-9) and 1.70  
0.68 g ethanol/kg (controls). After the first hour of ethanol
presentation, consumption in the 1–5 h interval was re-
duced significantly (P   0.015) in the ASO-9 group (0.48  
0.23 g ethanol/kg) compared with the control group
(1.22   0.16 g ethanol/kg) (Fig. 2). This equates to a 61%
reduction in ethanol consumption in ASO-9–treated ani-
mals after experiencing the drug (ASO-9) ethanol reaction.
Cumulative ethanol consumption at 5 h (which includes
the amount consumed in the first hour of presentation) was
Table II. Reduction of ALDH2 mRNA Levels by ASO-9
ALDH2
mRNA Inhibition
pg mRNA/
 g total RNA %
Experiment no. 1
Control oligo (1.0  M) 12.5 NAa
ASO-9 (1.0  M) 2.5 80
ASO-9 (0.5  M) 2.0 84
ASO-9 (0.25  M) 1.5 88
Experiment no. 2
Control oligo (1.0  M) 100 NA
ASO-9 (1.0  M) 3 97
Experiment no. 3
Control oligo (0.5  M) 25 NA
ASO-9 (0.5  M) 5 80
Experiment no. 4
2 bp mismatch of ASO-9 (1.0  M) 7.5 NA
ASO-9 (1.0  M) 2.5 67b
Experiment no. 5
Lipofectamine Plus (no ASO) 23.4 NA
ASO-9 (1.0  M) 4.7 80
Experiment no. 6
3 bp mismatch of ASO-9 (1.0  M) 12.95 NA
4 bp mismatch of ASO-9 (1.0  M) 21.8   8.3 NA
ASO-9 (1.0  M) 5.6    0.5 74b
Control oligonucleotide in experiments no. 1–3: 5 -CgTCT-
TCACTTCCgTgTAggC-3 ; 2 base mismatch of ASO-9 in experiment
no. 4: 5 -TCCTCg TTgTTCgCTTCg gCT-3 ; 3 base mismatch of
ASO-9 in experiment no. 5: 5 -TCCTCgTTgTTCgCATCg gCT-3 ;
4 base mismatch of ASO-9 in experiment no. 6: 5 -TCCACg TTg-
TACgCATCg gCT-3 .
aNA, not applicable.
bInhibition versus the 2-bp (Experiment no. 4) or 4-bp (Experiment
no. 6) mismatch. Mean inhibition by ASO-9: 84.8   4.7% was calcu-
lated from the six experiments shown above.
Figure 1. Quantitation of ALDH2–1 and GDH steady-state mRNA
by competitive RT-PCR. A1 and A2 show ALDH2 mRNA expression
and B1 and B2 show GDH mRNA expression. H4-II-E-C3 hepatoma
cells were incubated with Lipofectamine Plus™ in the presence of 1  M
ASO-9 (A1 and B1) or the 4-base mismatch of ASO-9 (A2 and B2, nu-
cleotide sequence in Table II). The concentration shown represents the
pg of ALDH2 mRNA competitor added/ g total RNA (A1 and A2) and
ng GDH mRNA competitor added/ g total RNA (B1 and B2). As can
be observed, lesser competitor was necessary to compete with ALDH2
mRNA in ASO-9–treated cells than in cells treated with the 4-base mis-
match of ASO-9 (control). In three replicates, the relative concentration
of ALDH mRNA for 4-base mismatch control cells was (indicated by ar-
rows) 21.8   8.3 pg/mg total RNA; that for the ASO-9–treated cells was
5.6   0.5 pg/mg total RNA. ASO-9 did not affect the GDH mRNA
levels when compared with the 4-base mismatch oligonucleotide. In
three replicates, the relative concentration of GDH mRNA for 4-base
mismatch control cells was (indicated by arrows) 9.65   0.19 ng/mg
total RNA; that for the ASO-9–treated cells was 9.26   0.18 ng/mg
total RNA.577 Garver et al.
1.599   0.23 g ethanol/kg (ASO-9) and 2.928   0.59 g
ethanol/kg (controls) corresponding to a 45% reduction
(P   0.035) in the total ethanol consumption in the ASO-
9–treated animals when compared with controls (Fig. 3 A).
This reduction is identical to the reduction (46%) in etha-
nol consumption experienced in earlier studies in rats
treated with disulfiram, a nonspecific drug used to induce
an aversion to ethanol (25; Fig. 3 B).
Discussion
The studies presented show that an antisense phos-
phorothioate deoxyoligonucleotide (ASO-9) was specific and
effective in reducing the de novo synthesis of mitochon-
drial ALDH2 in rat hepatoma cells. Given a 22-h half-life
for the mature enzyme, an inhibition of 95% in ALDH2
synthesis was calculated to occur after a 24-h incubation
with ASO-9. Actual remaining activity at 24 h was 55%.
Present knowledge indicates that there are two major
mechanisms of antisense action: (a) occupancy of mRNA
and (b) occupancy-activated RNase H hydrolysis of the
RNA targets (20). Our earlier studies on the mechanisms
of action of ASOs which incorporate the TCCC motif in
the molecule led to the finding that steady-state mRNA
levels are significantly reduced by these ASOs. As RNase H
only exists in the nucleus and the most effective ASOs had
targets mainly in intron and 3 -untranslated regions, it was
postulated that the TCCC-mediated mechanism of anti-
sense action was localized in the nucleus (22).
In the studies presented here, nine ASOs were designed
which incorporated the TCCC motif (22) targeting exons
(a message also present in the nucleus), as only the cDNA
sequence of the Sprague-Dawley rat ALDH2 was known
at the time of starting these studies (29). We found that
two of the nine antisense molecules (two ASO’s in 3 -
untranslated region [UTR], and seven ASOs in open read-
ing frame including ASO-9) had inhibitory effects on the
ALDH2 enzyme activity, with ASO-9 being the most ef-
fective. As ASO-9 targeted exon 2, it was possible that the
antisense mechanism of ASO-9 might have been due to
occupancy-mediated inhibition of translation rather than
to RNase H–mediated hydrolysis. To determine if the
mechanism of action followed translation arrest or a reduc-
tion in mRNA transcript levels, we determined the
steady-state levels of mRNA and whether any reduction
in mRNA levels correlated with the loss of ALDH2 activ-
ity. Analysis of ALDH2 steady-state mRNA by competi-
tive RT-PCR demonstrated that ASO-9 indeed reduced
the levels of mRNA by 85%, which paralleled the calcu-
lated 95% inhibition of enzyme synthesis. These data sug-
gest that the mechanism of action of ASO-9 is likely one
involving mRNA hydrolysis by RNase H, although some
additional transcriptional arrest by occupation cannot be
ruled out.
Table III. Reduction of the Steady-State Levels of ALDH2-1 and 
GDH mRNA after Treatment with PBS or ASO-9
ALDH2-1 GDH Inhibitiona
pg of mRNA/
 g total RNA 
ng of mRNA/
 g total RNA %
PBS
1 13.0 2.6 NAb
2 15.3 2.6 NA
3 16.1 2.3 NA
4 19.6   NA
16   1.4 2.5   0.1
ASO-9
1 7.4 2.3 53.8
2 9.6 2.7 40.0
3 6.4 2.6 60.0
4 8.4   47.5
8.0   0.7 2.5   0.1 50.3   4.2
t test of PBS versus ASO-9, P   0.007.
aInhibition for each animal in ASO-9 group calculated from mean
ALDH2-1 mRNA expression of PBS group.
bNA, not applicable.
Table IV. In Vivo Effect of ASO-9 Administration on the 
Activity of Liver ALDH2-1, GDH, and Plasma Acetaldehyde Levels 
after Administration of Ethanol (1 g/kg)
Treatment
group
ALDH
specific
activity
GDH
specific
activity ALDH/GDH
Plasma
acetaldehyde
nmol/min/
mg protein
 mol/min/
mg protein Ratio  M
PBS
1 58.9 6.4 9.2 1.5
2 48.2 6.4 7.5 1.9
3 42.9 8.4 7.0 3.6
4 58.9 8.4 7.0 3.6
52.2   4.0 7.1   0.5 7.4   0.7 2.2    1.0
ASO-9
1 37.5 7.7 4.9 7.5
2 37.5 7.7 4.9 6.1
3 32.2 8.4 3.8 7.5
4 42.9 8.4 5.1 8.1
5 37.5 7.7 4.9 9.4
6 32.2 7.7 4.2 11.4
36.6   1.6a 7.9   0.2b 4.6   0.2c 8.3   1.9d
ASO-9 (15 mg/kg/day) was administered intravenously to rats for 4 d.
24 h after the last dose of the oligonucleotide, animals received 1 g/kg
ethanol orally. Group values are means   SEM.
aEffect of ASO-9 on mitochondrial ALDH activity: P   0.01.
bEffect of ASO-9 on mitochondrial GDH activity: not significant.
cEffect of ASO-9 on ALDH/GDH ratio:   0.015.
dEffect of ASO-9 on plasma acetaldehyde levels:   0.002.578 Antisense-induced Aversion to Alcohol
A true antisense mechanism was demonstrated by the
fact that as the number of mismatches from the original
ASO-9 molecule were increased from 2- to 3- and 4 bases,
the oligonucleotide’s ability to inhibit ALDH mRNA lev-
els was reduced. An oligonucleotide with 4 base mis-
matches from ASO-9 was essentially inactive. Furthermore,
ASO-9 was specific for its ALDH2 target, as ALDH2
mRNA levels were reduced whereas the mRNA levels for
GDH, another mitochondrial enzyme, remained constant.
Despite the variation in basal mRNA levels in the H4
cells, the inhibition afforded by ASO-9 over six experi-
ments was quite constant and averaged 85%. During in
vitro studies it was noted that basal ALDH2 mRNA levels
varied between experiments. In each of these experiments,
serum was added at 6 h and the serum lots varied from one
experiment to another. Previously, it has been shown that
hormones such as insulin, progesterone, and dihydrotest-
osterone, found at different levels in serum lots, can in-
crease or reduce the expression of ALDH2 by as much as
50% (35). In addition, H4 cells at various passages were
used over the course of the experiments and we found that
the ALDH2 activity could be reduced by as much as 50%
after many ( 5) passages.
When “naked” (without liposomal conjugation) ASO-9
was administered intravenously for 4 d and animals were
killed 24 h after the last dose of the oligonucleotide, he-
patic ALDH2 mRNA was reduced by 50% and ALDH2
activity was reduced by 40%. Administration of ethanol to
animals pretreated with ASO-9 elicited a fourfold increase
in plasma acetaldehyde levels versus that in control (PBS)
animals. In the same animals, ASO-9 did not modify the
activity of mitochondrial GDH, thus again indicating the
specificity of action of this antisense oligonucleotide seen in
cell cultures.
We further determined if treatment of ASO-9 would es-
tablish an aversion to ethanol consumption in rats. We
have previously reported the development of a rat model to
measure a drug-induced aversion to ethanol using disul-
firam as the aversive test drug (25). Animals treated with
ASO-9 showed a 61% reduction in alcohol consumption
after experiencing the ASO-ethanol reaction compared
with control animals. Overall, ASO-9 showed an effective-
ness in the same order as that reported previously for large
doses of disulfiram.
Theoretically, an ASO of 17–21 bases with a sequence
complementary to the primary RNA transcripts or the
mRNA sequence can inhibit gene expression through
Watson-Crick DNA-RNA hybridization in a specific
manner because a sequence of this length is unlikely to re-
peat more than once in the human genome. Here, we
demonstrated that ASO-9 did not affect GDH activity or
mRNA levels, which strongly suggested that its effects
were not due to nonantisense effects on another protein. In
addition to specificity of antisense oligonucleotides for their
target, antisense oligonucleotides have been shown to have
minimal side effects over a wide range of doses (36). Both
the specificity and lack of serious side effects of an antisense
oligonucleotide would be advantageous when compared
with disulfiram.
Figure 2. Effect of ASO-9 on ethanol consumption after an 18-h water
deprivation period. Data show cumulative ethanol consumption (g etha-
nol/kg) by animals during the first 5 h of access to a 6% ethanol (vol/vol)
solution after an 18-h water deprivation. Prior to the study, rats received
ASO-9 (24 mg/kg/hr) or PBS for 4 d from implanted osmotic pumps.
Values represent mean   SEM for five animals. Ethanol consumption was
not significantly different in the two groups in the first hour of fluid reac-
cess. However, after the primal rehydration bout (and after experiencing a
combined ethanol-ASO-9 effect), rats that had received ASO-9 con-
sumed 61% less ethanol than control animals in the following 4 h (0.48 vs.
1.23 g ethanol/kg; P   0.015).
Figure 3. Comparison of the inhibitory effect on ethanol consumption
of ASO-9 (24 mg/kg/day) for 4 d (data from this study) and of disulfiram
administration (100 mg/kg/day) for 4 d (data from reference 25). The ef-
fect on ethanol consumption of ASO-9 and of disulfiram (a nonspecific
inhibitor of ALDHs), was determined after an 18-h water deprivation pe-
riod of inbred Lewis rats. Data show total ethanol consumption (g etha-
nol/kg) by animals during 5 h (zero to 5 h) of access to a 6% ethanol (vol/
vol) solution after the period of water deprivation. Control for disulfiram
was carboxymethyl-cellulose (CMC) in saline administered orally 2 h be-
fore fluid reaccess. Control for ASO-9 was PBS delivered continuously
from the osmotic pumps, which may account for the differences in fluid
consumption (6% ethanol) in the two control groups. The inhibitory ef-
fect on ethanol consumption of the two drugs (ASO-9 and disulfiram)
was identical (45 vs. 46%, not significant). DS, disulfiram. 579 Garver et al.
Disulfiram displays a large number of side effects, is non-
specific for its target, and requires daily administration,
which has markedly reduced its clinical use (15, 16). The
half-life of phosphorothioate oligonucleotides is 48 h in ro-
dents (37–39) while in humans, antisense molecules have
been reported to have a half-life of 6 to 14 d (40). The pro-
tracted half-life in humans would make it possible to re-
duce the frequency of administration, maintaining the de-
sired efficacy and improving compliance. Disulfiram is the
only drug that inhibits ALDH2 which is approved in the
U.S. for the treatment of alcoholism. Controlled studies
show that daily administration of disulfiram is indeed effec-
tive in the treatment of alcoholism (41, 42), although disul-
firam has been criticized for not lengthening the time
elapsed until full abstinence is broken (43). However, as
patients must experience the effects of the disulfiram-etha-
nol reaction before the aversive effects take place, the time
to break the abstinence is not expected to be affected by
the drug. The main problem with disulfiram relates to the
lack of compliance by patients with medication taking,
mainly due to sensory and motor neuropathies, optic neu-
ritis, orthostatic hypotension, and hypersensitivity reactions
(15–19). In a number of studies in which disulfiram was ad-
ministered under supervision its effectiveness in reducing
alcohol consumption was clearly seen (14). However, due
to its side effects, doses that are fully therapeutic are rarely
achieved. At the doses normally employed (250–300 mg
daily), less than 50% of patients display the disulfiram-etha-
nol reaction (44, 45). Thus, there is the obvious need to
develop alternatives to disulfiram to mimic the strong pro-
tective effects of a low ALDH2 activity seen in Asians car-
rying the ALDH2–2 allele.
Studies presented in this communication provide a
strong proof of principle that inhibition of ALDH2 gene
expression can mimic the ALDH2–2 Asian phenotype, re-
sulting in (a) low liver mitochondrial ALDH2–1 activity,
(b) elevated plasma acetaldehyde levels after the administra-
tion of ethanol, and (c) an aversion to ethanol, shown as a
reduction in alcohol consumption.
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